Peptide hormone

Peptide hormone signaling constitutes a major class of intercellular communication that is fundamentally distinct from the lipophilic steroid hormones and the rapid, point-to-point transmission of neuronal synapses. Peptide hormones, which include insulin, glucagon, parathyroid hormone (PTH), and a vast array of other polypeptides ranging from small oligopeptides to large glycoproteins, are synthesized as precursor prohormones in endocrine cells, processed through the regulated secretory pathway, and released into the circulation upon specific physiological stimuli (Hutton, 1990). Unlike steroid hormones, peptide hormones are hydrophilic and therefore cannot passively cross the plasma membrane; instead, they exert their actions exclusively by binding to cell-surface receptors, initiating intracellular signaling cascades that are typically rapid, reversible, and highly amplified (Pierce et al., 2002). This mode of signaling is ideally suited for the acute regulation of metabolism, calcium homeostasis, growth, and stress responses.

The biosynthesis of peptide hormones follows a conserved pathway. The preprohormone, containing an N-terminal signal peptide, is synthesized on rough endoplasmic reticulum (ER), where the signal peptide is cleaved to yield the prohormone (Lodish et al., 2000). Subsequent folding, disulfide bond formation, and proteolytic processing occur in the ER and Golgi apparatus, often by prohormone convertases such as PC1/3 and PC2, which cleave at pairs of basic amino acid residues (Seidah & Chrétien, 1999). The mature hormone is then packaged into secretory vesicles, which undergo exocytosis in response to specific secretagogues—for instance, elevated blood glucose triggers insulin exocytosis from pancreatic β-cells, while hypocalcemia stimulates PTH secretion from parathyroid chief cells (Ashcroft & Rorsman, 2012; Brown, 1991). Once released, peptide hormones typically circulate in free solution, unbound to carrier proteins, and therefore exhibit short half-lives, ranging from minutes to a few hours, necessitating continuous secretion for sustained effects (Van Loon, 1990).

The mechanisms of peptide hormone action are mediated by three major classes of cell-surface receptors: G protein-coupled receptors (GPCRs), receptor tyrosine kinases (RTKs), and cytokine receptors (also known as Janus kinase-associated receptors). GPCRs, which bind PTH, glucagon, and countless other peptide hormones, are seven-transmembrane domain receptors that couple to heterotrimeric G proteins, leading to activation of second messenger systems such as cyclic AMP (cAMP) via adenylyl cyclase, or inositol trisphosphate (IP3) and diacylglycerol (DAG) via phospholipase C (Pierce et al., 2002). For example, PTH binds to its GPCR, the PTH1 receptor, which activates both adenylyl cyclase and phospholipase C pathways in bone and kidney, mediating the classical actions on calcium homeostasis and bone remodeling (Jüppner et al., 1991). Glucagon acts through its GPCR on hepatocytes to elevate intracellular cAMP, thereby activating protein kinase A (PKA) and promoting glycogenolysis and gluconeogenesis (Jiang & Zhang, 2003). In contrast, insulin binds to an RTK, specifically the insulin receptor, which is a tetramer composed of two extracellular α-subunits and two transmembrane β-subunits with intrinsic tyrosine kinase activity (Saltiel & Kahn, 2001). Ligand binding induces autophosphorylation of the β-subunits, which then phosphorylate downstream adaptor proteins, including insulin receptor substrates (IRS) and Shc, leading to activation of the PI3K/Akt pathway (mediating metabolic effects such as GLUT4 translocation and glycogen synthesis) and the MAPK/ERK pathway (mediating mitogenic and growth effects) (White, 2003). Cytokine receptors, exemplified by receptors for growth hormone and prolactin, lack intrinsic kinase activity but associate with cytosolic Janus kinases (JAKs), which phosphorylate signal transducers and activators of transcription (STATs) that subsequently translocate to the nucleus to regulate gene expression (Argetsinger & Carter-Su, 1996).

A critical feature of peptide hormone signaling is signal amplification and termination. The binding of a single hormone molecule to its receptor can activate numerous G proteins or kinase cascades, resulting in the generation of thousands of second messenger molecules and phosphorylation of multiple downstream targets, thereby achieving enormous signal amplification (Ferrell, 2002). Conversely, signal termination is equally crucial and occurs at multiple levels: hormone degradation by peptidases (e.g., the insulin-degrading enzyme), receptor desensitization and internalization, dephosphorylation by protein phosphatases, and degradation of second messengers by phosphodiesterases (Lefkowitz et al., 1998). For instance, GPCRs are desensitized by G protein-coupled receptor kinases (GRKs) and arrestins, which uncouple the receptor from G proteins and target it for clathrin-mediated endocytosis (Krupnick & Benovic, 1998). This dynamic balance between activation and termination allows peptide hormones to provide exquisitely controlled, pulsatile, and adaptive responses to changing physiological conditions.

The physiological roles of major peptide hormones underscore the importance of this signaling mode. Insulin is the primary anabolic hormone, promoting glucose uptake in muscle and adipose tissue, glycogenesis, lipogenesis, and protein synthesis, while inhibiting gluconeogenesis and lipolysis (Saltiel & Kahn, 2001). Glucagon exerts counter-regulatory effects, mobilizing hepatic glucose production and fatty acid oxidation during fasting (Jiang & Zhang, 2003). The interplay between these two hormones maintains euglycemia; their dysregulation underlies diabetes mellitus, a global pandemic affecting over 500 million individuals (American Diabetes Association, 2022). PTH, together with calcitonin and vitamin D, tightly regulates extracellular calcium and phosphate concentrations by acting on bone, kidney, and intestine: PTH stimulates osteoclastic bone resorption, enhances renal calcium reabsorption and phosphate excretion, and promotes the renal synthesis of active vitamin D (1,25-dihydroxyvitamin D), which in turn increases intestinal calcium absorption (Silva & Bilezikian, 2015). Dysregulated PTH secretion is responsible for primary hyperparathyroidism (excess PTH) and hypoparathyroidism (deficient PTH), each with characteristic derangements in mineral metabolism and skeletal integrity.

In addition to these classical endocrine actions, peptide hormones also exhibit paracrine and autocrine effects, blurring the traditional boundaries of endocrine classification. For example, insulin-like growth factor-1 (IGF-1) is produced in the liver as an endocrine hormone under growth hormone control but is also synthesized in multiple peripheral tissues, where it acts locally in a paracrine or autocrine manner to promote growth and differentiation (LeRoith et al., 2001). Similarly, the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are secreted by intestinal L-cells and K-cells, respectively, and act on pancreatic β-cells to potentiate glucose-stimulated insulin secretion, representing a crucial entero-pancreatic axis that is now therapeutically exploited with GLP-1 receptor agonists for the treatment of type 2 diabetes and obesity (Drucker, 2006).

Therapeutic targeting of peptide hormone signaling is a cornerstone of modern medicine. Exogenous insulin remains life-saving for type 1 diabetic patients and is essential for many with advanced type 2 diabetes; its delivery has been refined through the development of rapid-acting and long-acting analogs with improved pharmacokinetic profiles (Bolli et al., 1999). PTH analogs, such as teriparatide, are anabolic agents used to treat osteoporosis by stimulating bone formation, representing a therapeutic paradigm shift from antiresorptive therapies (Neer et al., 2001). Glucagon is used as an emergency rescue therapy for severe hypoglycemia. Moreover, peptide receptor antagonists and agonists are being developed for diverse applications, including somatostatin analogs for neuroendocrine tumors and calcitonin gene-related peptide (CGRP) antagonists for migraine. However, the peptide nature of these molecules imposes limitations, including the need for parenteral administration due to poor oral bioavailability, rapid proteolytic degradation, and the potential for immunogenicity, driving ongoing research into peptide mimetics, sustained-release formulations, and alternative delivery routes (Fosgerau & Hoffmann, 2015).

References

American Diabetes Association. (2022). Standards of medical care in diabetes—2022. Diabetes Care, 45(Suppl 1), S1–S264.

Argetsinger, L. S., & Carter-Su, C. (1996). Mechanism of signaling by growth hormone receptor. Physiological Reviews, 76(4), 1089–1107.

Ashcroft, F. M., & Rorsman, P. (2012). Diabetes mellitus and the β cell: The last ten years. Cell, 148(6), 1160–1171.

Bolli, G. B., Di Marchi, R. D., Park, G. D., et al. (1999). Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia, 42(10), 1151–1167.

Brown, E. M. (1991). Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiological Reviews, 71(2), 371–411.

Drucker, D. J. (2006). The biology of incretin hormones. Cell Metabolism, 3(3), 153–165.

Ferrell, J. E. (2002). Self-perpetuating states in signal transduction: Positive feedback, double-negative feedback and bistability. Current Opinion in Cell Biology, 14(2), 140–148.

Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: Current status and future directions. Drug Discovery Today, 20(1), 122–128.

Hutton, J. C. (1990). Subtilisin-like proteinases involved in the activation of proproteins of the eukaryotic secretory pathway. Current Opinion in Cell Biology, 2(6), 1131–1142.

Jiang, G., & Zhang, B. B. (2003). Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism, 284(4), E671–E678.

Jüppner, H., Abou-Samra, A. B., Freeman, M., et al. (1991). A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science, 254(5034), 1024–1026.

Krupnick, J. G., & Benovic, J. L. (1998). The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annual Review of Pharmacology and Toxicology, 38, 289–319.

Lefkowitz, R. J., Pitcher, J., Krueger, K., & Daaka, Y. (1998). Mechanisms of β-adrenergic receptor desensitization and resensitization. Advances in Pharmacology, 42, 416–420.

LeRoith, D., Bondy, C., Yakar, S., Liu, J. L., & Butler, A. (2001). The somatomedin hypothesis: 2001. Endocrine Reviews, 22(1), 53–74.

Lodish, H., Berk, A., Zipursky, S. L., et al. (2000). Molecular Cell Biology (4th ed.). W. H. Freeman.

Neer, R. M., Arnaud, C. D., Zanchetta, J. R., et al. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New England Journal of Medicine, 344(19), 1434–1441.

Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). Seven-transmembrane receptors. Nature Reviews Molecular Cell Biology, 3(9), 639–650.

Saltiel, A. R., & Kahn, C. R. (2001). Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799–806.

Seidah, N. G., & Chrétien, M. (1999). Proprotein and prohormone convertases: A family of subtilases generating diverse bioactive polypeptides. Brain Research, 848(1-2), 45–62.

Silva, B. C., & Bilezikian, J. P. (2015). Parathyroid hormone: Anabolic and catabolic actions on the skeleton. Current Opinion in Pharmacology, 22, 41–50.

Van Loon, G. R. (1990). Antibodies and the study of peptide hormone function. Methods in Enzymology, 184, 344–364.

White, M. F. (2003). Insulin signaling in health and disease. Science, 302(5651), 1710–1711.